5728-40-5

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-4-phenylbenzoic acid is used as a key intermediate in the synthesis of various pharmaceutical compounds for its potential applications in the development of anti-inflammatory, analgesic, and anti-cancer drugs. Its specific properties and reactivity contribute to the creation of novel therapeutic agents that can address unmet medical needs.
Used in Medicinal and Biochemical Research:
2-Chloro-4-phenylbenzoic acid serves as a valuable tool in medicinal and biochemical research, enabling the exploration of its potential applications in drug discovery and development. Its unique chemical structure and reactivity facilitate the design and synthesis of new bioactive molecules with therapeutic potential.
Used in Material Science and Organic Electronics:
2-Chloro-4-phenylbenzoic acid has been studied for its potential use in the development of new materials and organic electronics. Its chemical properties and reactivity make it a promising candidate for the creation of innovative materials with unique electronic, optical, or mechanical properties, contributing to advancements in various technological fields.

Upstream product

• 124-38-9 carbon dioxide 
• 91354-08-4 4-bromo-3-chloro-1,1'-biphenyl 
• 5435-92-7 3-chloro-[1,1'-biphenyl]-4-carbonitrile 
• 7285-66-7 3-chlorobiphenyl-4-amine 
• 145343-76-6 2-chloro-4-iodobenzoic acid 
• 1124-19-2 phenyltin trichloride 
• 59748-90-2 4-Bromo-2-chloro-benzoic Acid 
• 98-80-6 phenylboronic acid 

Downstream Products

• 854241-75-1 3-diphenylamino-biphenyl-4-carboxylic acid 
• 857571-73-4 3,10-diphenyl-10H-acridin-9-one 
• 910242-29-4 3-anilino-biphenyl-4-carboxylic acid 

Relevant academic research and scientific papers

Design, synthesis, and structure-activity relationship studies of L-amino alcohol derivatives as broad-spectrum antifungal agents

To discover broad spectrum antifungal agents, two strategies were applied, and a novel class of L-amino alcohol derivatives were designed and synthesized. 3-F substituted compounds 14i, 14n, 14s and 14v exhibited excellent antifungal activities with broad antifungal spectra against C. albicans and C. tropicalis, with MIC values in the range of 0.03–0.06 μg/mL, and against A. fumigatus and C. neoformans, with MIC values in the range of 1–2 μg/mL. Notably, Compounds 14i, 14n, 14s and 14v also displayed moderate activities against fluconazole-resistance strains 17# and CaR that were isolated from AIDS patients. Moreover, only compounds in the S-configuration showed antifungal activity. Preliminary mechanistic studies showed that the potent antifungal activity of compound 14v stemmed from inhibition of C. albicans CYP51. Compounds 14n and 14v were almost nontoxic to mammalian A549 cells, and their stability in human plasma was excellent.

Design, synthesis and evaluation of biphenyl imidazole analogues as potent antifungal agents

To further explore the structure activity relationships (SARs) of our previously discovered antifungal lead compound (1), a series of biphenyl imidazole analogues were designed, synthesized and evaluated for their in vitro antifungal activity. Many of the

Combating fluconazole-resistant fungi with novel β-azole-phenylacetone derivatives

A series of β-azole-phenylacetone derivatives with novel structures were designed and synthesized to combat the increasing incidence of susceptible fungal infections and drug-resistant fungal infections. The antifungal activity of the synthesized compounds was assessed against five susceptible strains and five fluconazole-resistant strains. Antifungal activity tests showed that most of the compounds exhibited excellent antifungal activities against five pathogenic strains with MIC values in the range of 0.03–1 μg/mL. Compounds with R1 = 3-F substituted and 15o and 15ae exhibited moderate antifungal activities against fluconazole-resistant strains 17# and CaR with MIC values in the range of 1–8 μg/mL. Compounds with R1 = H or 2-F (such as 15a, 15o, 15p) displayed moderate to good antifungal activity against fluconazole-resistant strains 632, 901 and 904 with MIC values in the range of 0.125–4 μg/mL. Notably, 15o and 15ae exhibited antifungal activity against five susceptible strains and five fluconazole-resistant strains. Preliminary mechanistic studies showed that the potent antifungal activity of compound 15ae stemmed from inhibition of C. albicans CYP51. Compounds 15o, 15z and 15ae were nearly nontoxic to mammalian A549 cells.

Exploring the mechanism of Stille C-C coupling via peptide-capped Pd nanoparticles results in low temperature reagent selectivity

Herein we systematically probed the atom-leaching mechanism of Pd nanoparticle-driven Stille coupling to further elucidate the fate of the highly active Pd0 atoms released in solution. In this regard, initial oxidative addition at the particle surface results in Pd atom abstraction for reactivity in solution. As a result, two reaction sites are present, the particle surface and pre-leached Pd atoms, thus different degrees of reactivity are possible. This effect was probed via aryl halide combinations that varied the halogen identity allowing for oxidative addition of two substrates simultaneously. The results demonstrate that the system was highly reactive for iodo-based compounds in the mixture at room temperature; however, reactivity at bromo-based substrates was only observed at slightly elevated temperatures of 40.0 °C. As such, substrate selectivity was evident from the catalytic materials that can be controlled based upon the aryl halide composition and reaction temperature. Furthermore, both intermolecular and intramolecular selectivity is possible, thus raising the degree of reaction complexity that can be achieved.

INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS

The present invention relates to compounds of Formula I: I which are agonists of the M-1 muscarinic receptor.

MUSCARINIC AGONISTS

The present invention relates to compounds of Formula (I): which are agonists of the M-1 muscarinic receptor.

MUSCARINIC AGONISTS

The present invention relates to compounds of Formula (I): which are agonists of the M-1 muscarinic receptor.

CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME

The present invention provides a novel carboxylic acid compound, a salt thereof or a hydrate of them useful as an insulin-resistant improver, and a medicament comprising the compound as an active ingredient. That is, the present invention provides a carboxylic acid compound represented by the following formula (I), a salt thereof, an ester thereof or a hydrate of them. In the formula, R1 represents hydrogen atom, hydroxyl group or a C1-6 alkyl group etc. which may have one or more substituents; L represents a single or double bond or a C1-6 alkylene group etc. which may have one or more substituents; M represents a single bond or a C1-6 alkylene group etc. which may have one or more substituents; T represents a single bond or a C1-3 alkylene group which may have one or more substituents; W represents carboxyl group or a group represented by the formula -CON(Rw1)Rw2 (wherein Rw1 and Rw2 are the same as or different from each other and each represents hydrogen atom, formyl group etc.) etc.; represents a single or double bond; X represents oxygen atom or a C2-6 alkenylene group etc. which may have one or more substituents; Y represents a C5-12 aromatic hydrocarbon group etc. which may have one or more substituents and which may have one or more heteroatoms; and ring Z represents a C5-6 aromatic hydrocarbon group which may have 0 to 4 substituents and which may have one or more heteroatoms.